… Hereditary angioedema therapy relies on treatment of acute attacks, and short- and long-term …
with C1-INH concentrate, icatibant or ecallantide; tranexamic acid or androgens are …

… acute treatment for angioedema has been fundamental in reducing the burden of illness for
patients with hereditary angioedema (HAE… The plasma kallikrein inhibitor ecallantide and the …

… on the management of hereditary angioedema (HAE) and … , ecallantide (30 mg subcutaneous)
was tested specifically in patients with hereditary angioedema suffering laryngeal attacks …

… , so patients are unable to treat acute attacks at home.Additionally, finding a medical facility
at … demonstrate efficacy of icatibant in treating acute attacks in patients with the PLG mutation.…

… to treat severe life-threatening attacks … ecallantide in patients with hereditary angioedema
[Citation40,Citation41,Citation44]. The results for 30 mg subcutaneous injection of ecallantide …

… 0.786 for ecallantide. At a mean annual attack rate of 26.9, cost per QALY was $402,769 for
rhC1-INH, $475,942 for icatibant, $462,275 for pdC1-INH, and $666,153 for ecallantide. Re-…

… of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann …
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks…

… (SC) kallikrein inhibitor ecallantide (KALBITOR), or the SC … treatment is important to minimize
progression of an attack, … or a caregiver upon attack onset, with the exception of ecallantide, …

… replacement therapy during acute attacks or for their prophylaxis, other drugs have been
developed, namely bradykinin and kallikrein inhibitors (icatibant, ecallantide, and lanadelumab)…

… treatment of acute attacks of hereditary angioedema: the FAST-3 … Ecallantide (DX-88) for
acute hereditary angioedema attacks: … Critical role of kallikrein in hereditary angioedema …